DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR MS Speaks
       *****************************************************
   DIR LUCID-MS gets FDA IND clearance, advances toward phase 2 trial
       0 replies
   DIR Rituxan (rituximab)
       32 replies
   DIR (Abst.) Age and treatment class modify inflammatory risk after...
       0 replies
   DIR (Abst.) Predictors of high- vs. low-intensity first-line MS tr...
       0 replies
   DIR (Abst.) Effectiveness of escalation vs. early high-efficacy th...
       0 replies
   DIR (Abst.) Comparative effectiveness of ofatumumab and ocrelizuma...
       0 replies
   DIR Rituximab vs. ocrelizumab in newly diagnosed relapsing MS
       0 replies
   DIR MS Journal commentary on whether all anti-CD20 therapies are e...
       0 replies
   DIR (Abst.) Treatment escalation after clinically silent MRI lesio...
       0 replies
   DIR UTIs, urosepsis, and MS DMTs: A disproportionality analysis of...
       0 replies
       *****************************************************
       Page 1 of 30
   DIR Next Page